Potential Ligands to Resistin Against Prostate Cancer, Evaluated by Molecular Docking and In Vitro Assays to Develop an Anticancer Drug.

Overweight and obesity are risk factors that increase the white adipose tissue (WAT) that promotes the release of adipokines (adiponectin, leptin, and resistin). The increase of the resistin levels contributes to different cellular processes; regulation in the metabolism, inflammation process, and particularly in messengers in some cancer types. Resistin promotes cell proliferation and migration. Therefore, resistin is proposed as a multipotential therapeutic target to treat different diseases, and in this study, we focus on the regulation of resistin and its effect on prostate cancer. This study proposes compounds selective to resistin, these were selected and evaluated by molecular docking and in vitro assays, to develop a new drug against the resistin´s functions related to interaction with their potential receptors (Δ-DCN, TLR4, and CAP-1). These molecules with pharmacological characteristics are capable of interacting in the regions of resistin to hinder/block the interaction between resistin and their possible receptors (Δ-DCN, TLR4, and CAP-1). We determined two compounds that showed to be selective against resistin by in vitro assays. In this way, this study proposes compounds that were developed to be selective against resistin, and it could decrease the effect known of resistin by their receptors related to the proliferation of cancer.